These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6151328)

  • 1. Thyroid stimulating immunoglobulins in Graves' disease with goitre growth, low thyroxine and increasing triiodothyronine during PTU treatment.
    Hegedüs L; Hansen JM; Bech K; Kampmann JP; Jensen K; Andersen E; Hansen P; Karstrup S; Bliddal H
    Acta Endocrinol (Copenh); 1984 Dec; 107(4):482-8. PubMed ID: 6151328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationships between serum T3 index, thyroid volume, and thyroid stimulating, TSH receptor binding and thyroid growth stimulating antibodies in untreated Graves' disease.
    Bliddal H; Hegedüs L; Hansen JM; Bech K; van der Gaag R; Drexhage HA
    Clin Endocrinol (Oxf); 1987 Jul; 27(1):75-84. PubMed ID: 2888551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Syndrome of persisting thyroid stimulating immunoglobulins and growth promotion of goiter combined with low thyroxine and high triiodothyronine serum levels in drug treated Graves' disease.
    Wenzel KW; Lente JR
    J Endocrinol Invest; 1983 Oct; 6(5):389-94. PubMed ID: 6141202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of thyroid stimulating antibodies and TSH-binding inhibiting immunoglobulins in the follow-up of Graves' disease.
    Hörmann R; Saller B; Müller R; Mann K
    Klin Wochenschr; 1985 Dec; 63(24):1247-52. PubMed ID: 2868149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.
    Romaldini JH; Bromberg N; Werner RS; Tanaka LM; Rodrigues HF; Werner MC; Farah CS; Reis LC
    J Clin Endocrinol Metab; 1983 Sep; 57(3):563-70. PubMed ID: 6192139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
    Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
    J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of remission after antithyroid drug treatment in Graves' disease.
    Young ET; Steel NR; Taylor JJ; Stephenson AM; Stratton A; Holcombe M; Kendall-Taylor P
    Q J Med; 1988 Feb; 66(250):175-89. PubMed ID: 2902655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Graves' disease in pregnancy: TSH receptor binding inhibiting immunoglobulins and maternal and neonatal thyroid function.
    Mortimer RH; Tyack SA; Galligan JP; Perry-Keene DA; Tan YM
    Clin Endocrinol (Oxf); 1990 Feb; 32(2):141-52. PubMed ID: 1971773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similar effects of thionamide drugs and perchlorate on thyroid-stimulating immunoglobulins in Graves' disease: evidence against an immunosuppressive action of thionamide drugs.
    Wenzel KW; Lente JR
    J Clin Endocrinol Metab; 1984 Jan; 58(1):62-9. PubMed ID: 6196375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of parallel measurements of thyrotropin binding inhibiting immunoglobulins (TBII) and thyroid adenylate cyclase stimulating antibodies (TSAb) in Graves' disease after longterm antithyroid treatment.
    Bliddal H; Bech K; Siersbaek-Nielsen K; Friis T
    J Endocrinol Invest; 1983 Aug; 6(4):259-62. PubMed ID: 6139399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The assay of Graves' immunoglobulins: a comparison of different methods.
    Hardisty CA; Kendall-Taylor P; Atkinson S; Humphries H; Munro DS
    Clin Endocrinol (Oxf); 1983 Jun; 18(6):637-44. PubMed ID: 6136348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of the course of Graves' disease after medical antithyroid treatment.
    Eshøj O; Kvetny J; Mogensen EF; Bech K; Bliddal H
    Acta Med Scand; 1985; 217(2):225-8. PubMed ID: 2859737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graves' disease and Hashimoto's thyroiditis: effects of high doses of antithyroid drugs on thyroid autoantibody levels.
    Romaldini JH; Werner MC; Rodrigues HF; Teixeira VL; Werner RS; Farah CS; Bromberg N
    J Endocrinol Invest; 1986 Jun; 9(3):233-8. PubMed ID: 2428860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection and properties of TSH-binding inhibitor immunoglobulins in patients with Graves' disease and Hashimoto's thyroiditis.
    Endo K; Kasagi K; Konishi J; Ikekubo K; Okuno T; Takeda Y; Mori T; Torizuka K
    J Clin Endocrinol Metab; 1978 May; 46(5):734-9. PubMed ID: 45421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroid adenylate cyclase stimulating immunoglobulins in thyroid diseases.
    Bech K; Nistrup Madsen S
    Clin Endocrinol (Oxf); 1979 Jul; 11(1):47-58. PubMed ID: 583261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ratio of serum triiodothyronine to thyroxine and the prognosis of triiodothyronine-predominant Graves' disease.
    Takamatsu J; Sugawara M; Kuma K; Kobayashi A; Matsuzuka F; Mozai T; Hershman JM
    Ann Intern Med; 1984 Mar; 100(3):372-5. PubMed ID: 6546484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
    Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
    Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of TSH-receptor antibodies as prognostic markers after cessation of antithyroid drug treatment in patients with Graves' disease.
    Kasagi K; Iida Y; Hatabu H; Tokuda Y; Arai K; Endo K; Konishi J
    Acta Endocrinol (Copenh); 1988 Feb; 117(2):173-80. PubMed ID: 2454576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.